Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Chao Yan Co., Ltd., particularly in the medical device industry, where it has a high PE ratio compared to industry averages [1][2] - As of December 12, Chao Yan Co., Ltd. closed at 22.3 yuan, with a rolling PE ratio of 67.17 times and a total market capitalization of 9.552 billion yuan [1] - The company ranks 102nd in the medical device industry, which has an average PE ratio of 50.65 times and a median of 38.17 times [1][2] Group 2 - As of the third quarter of 2025, nine institutions hold shares in Chao Yan Co., Ltd., with a total of 4.3483 million shares valued at 107 million yuan [1] - The main business of Chao Yan Co., Ltd. includes the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [1] - The latest financial results for the third quarter of 2025 show that the company achieved an operating income of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit of 88.9445 million yuan, a year-on-year decrease of 3.66%, with a sales gross margin of 73.20% [1]

点击免费限量礼盒 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 12月9日，九强生物晚间发布公告称，公司股东邹左军、刘希、孙小林与 中国医药投资有限公司（以下简称"国药投资"） 签署《股份转让协 议》，前者拟通过协议转让方式向国药投资合计转让2931.54万股股份，占九强生物总股的5%，交易总价款达4.01亿元，每股转让价格为 13.68元。 主营业务为生化诊断、血凝检测、血型检测和肿瘤病理检测的研发、生产和销售。2020年，在国药投资正式成为九强生物第一大股东后，九强 生物与国药投资联手收购迈新生物，布局肿瘤筛查诊断，扩充病理诊断试剂和仪器产品线，提升技术研发能力和营销网络布局。 在福布斯排行榜中，九强生物是全国中小企业中唯一一家连续9年上榜的中国潜力100强企业 。 | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号 立 场 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 责 编 ： 安 安 | 视 觉 ： 长 艳 柱 ...

（编辑 丛可心） 证券日报网讯 12月11日晚间，九强生物发布公告称，公司近日获国家知识产权局颁发的1项发明专利证 书，专利号ZL202510542311.9，名称为"应用于凝血分析仪的反应杯导向和自润滑机构"，授权日2025年 12月5日，专利权期限20年。 ...

（文章来源：北京商报） 北京商报讯12月11日，九强生物发布公告称，公司于近期收到国家知识产权局颁发的1项专利证书，专 利名称为应用于凝血分析仪的反应杯导向和自润滑机构，专利号为ZL202510542311.9。 根据公告，该发明涉及一种应用于凝血分析仪的反应杯导向和自润滑机构，包括基座、环形压紧块、夹 紧弹性体，能够提高反应杯的定位精度，并提高反应杯放入反应杯安装腔后光学通道的清洁程度，从而 保证了检测的准确性，并且不再需要频繁清理光学通道。 ...

九强生物12月11日公告，公司近日获得一项发明专利证书，专利名称为"应用于凝血分析仪的反应杯导 向和自润滑机构"，专利号为ZL202510542311.9。该发明涉及一种反应杯导向和自润滑机构，包括基 座、环形压紧块和夹紧弹性体，能够提高反应杯的定位精度，并提高反应杯放入反应杯安装腔后光学通 道的清洁程度，从而保证了检测的准确性。该发明专利不会对公司近期生产经营产生重大影响，但有利 于发挥公司的知识产权优势，促进技术创新，提升公司的核心竞争力，并形成持续创新机制。 ...

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-117 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司（以下简称"九强生物"或"公司"）于近 期收到中华人民共和国国家知识产权局颁发的 1 项专利证书，具体情况如下： 一、专利基本情况 | 序号 | 专利号 | 专利名称 | 专利权人 | 专利类型 | 申请日期 | 授权日期 | | 证书号 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 应用于凝血 分析仪的反 | | | | | | | | | 1 | ZL202510 | | 九强生物 | 发明 | 2025.04.27 | 2025.12.05 | 第 | 8549691 | 号 | | | 542311.9 | 应杯导向和 | | | | | | | | | | | 自润滑机构 | | | | | | | | 注：发明专利权期限为自申请日起二十年。 北京九强生物技术股份有限公司 发明专利摘要： 关 ...

Group 1 - Jinggong Technology signed a sales contract with Hubei Yuchuang worth 729 million yuan, accounting for 42.16% of the company's audited revenue for 2024 [1] - Heshun Electric is expected to win a bid for a State Grid procurement project worth 107 million yuan, representing 24.97% of the company's 2024 revenue [2] - Yongmaotai plans to invest approximately 400 million yuan in a new intelligent manufacturing project for magnesium-aluminum alloy materials [3] Group 2 - Longi Green Energy announced the termination of its plan to issue global depositary receipts abroad, stating it will not significantly impact its operations [4] - Bai Ao Intelligent is expected to win bids for projects totaling 27.5 million yuan [5] - Lian Biological is planning a change of control and asset purchase, leading to a temporary suspension of its stock [6] Group 3 - Bo Rui Communication intends to acquire 51% of Meijing Technology for 66.49 million yuan [7] - Huitai Medical plans to repurchase shares worth 200 to 250 million yuan for employee stock ownership plans [8] - Yifang Biological is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] Group 4 - Jiuqiang Biological's shareholders signed an agreement for the transfer of 5% of the company's shares to China National Pharmaceutical Investment [11] - Songcheng Performing Arts plans to repurchase shares worth 100 to 200 million yuan for capital reduction [12] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project in Jiangxi Province [13] Group 5 - Xingfu Electronics plans to invest 480 million yuan in a new electronic-grade phosphoric acid project [14] - Jiaao Environmental Protection's stock will be subject to risk warnings due to an administrative penalty [15] - ST Nuotai received a drug registration certificate for a new injection [16] Group 6 - Haimo Technology plans to sell its controlling subsidiary, Xian Sitian Instrument, for 370 million yuan [17] - Jingce Electronics signed multiple sales contracts with a single customer totaling 433 million yuan [18] - Donghua Testing's controlling shareholder plans to reduce its stake by up to 1.99% [19][20] Group 7 - Xingqi Eye Medicine completed the first subject enrollment for a Phase II clinical trial of its eye drop product [21] - Kute Intelligent's controlling shareholder plans to reduce its stake by up to 2% [22] - Dongcheng Pharmaceutical's subsidiary received approval for a new specification of a heparin sodium injection [23] Group 8 - Zhaoyi Innovation is in the process of issuing H-shares and has received regulatory approval [24] - Aokang International's shareholder plans to reduce its stake by up to 3% [25] - Jiamei Packaging's controlling shareholder is planning a change of control, leading to a temporary stock suspension [26] Group 9 - ST Kevin's stock will have its risk warning lifted and will resume trading [27] - Zaiseng Technology's controlling shareholder plans to transfer 6.04% of the company's shares [28] - Lide New Energy's shareholder plans to reduce its stake by up to 1% [29] Group 10 - Srypu terminated its plan to acquire shares and will resume trading [30] - Longjiang Transportation's subsidiary plans to invest 2.679 billion yuan in a graphite mining project [31] - Haowei Group's controlling shareholder has not reduced its stake and has terminated the reduction plan [32] Group 11 - Huilun Crystal received an administrative penalty notice for information disclosure violations [33] - Haiguang Information terminated a major asset restructuring plan [34] - Zhongke Shuguang announced a cash dividend plan [35] Group 12 - Fushuo Technology's share purchase plan was approved by the Shenzhen Stock Exchange [36] - Dongbai Group's shareholder reduced its stake by 25.95 million shares [38]

国药投资承诺，本次受让的股份自交割日起18个月内不得转让，若监管要求有更严格限售规定则从其规 定。同时，标的股份过户完成后30日内，国药投资有权向九强生物提名1名非独立董事候选人，替换现 任董事罗爱平，转让方将配合完成相关选举程序。 九强生物表示，本次权益变动不触及要约收购，不会导致公司控股股东、实际控制人变更，对公司治理 结构及持续经营无重大影响。 资料显示，国药投资成立于1986年12月18日，是中国医药集团有限公司（下称"国药集团"）100%控股 的法人独资企业，实际控制人为国药集团，最终控制方为国务院国资委。 财务数据显示，2022年—2024年，国药投资净利润分别为11.94亿元、16.17亿元、14.10亿元，资产负债 率始终保持在5.25%—6.70%的较低水平。 值得注意的是，国药投资长期持续增持九强生物。回溯历史权益变动，自2020年7月披露《详式权益变 动报告书》后，国药投资通过多种方式不断提升持股比例：2022年4月27日至6月23日，通过大宗交易和 集中竞价增持367万股；2022年8月24日至2023年1月5日，再次增持515.22万股；2024年6月24日至25日 增持182.7万 ...

Core Viewpoint - The article discusses the approval of 26 innovative medical devices by the National Medical Products Administration (NMPA) and local regulatory bodies in China, focusing on advancements in various medical technologies and their potential impact on healthcare [34]. Group 1: Overview of Approved Devices - A total of 26 medical devices have entered the innovative approval channel, with 10 products approved by the NMPA and 16 by local authorities [34]. - The applications are primarily concentrated in Shanghai, Jiangsu, and Guangdong provinces, covering 11 categories of medical devices, mainly focusing on active surgical instruments, passive implantable devices, and passive surgical instruments [36]. Group 2: Notable Devices and Companies - **Renal Artery Ultrasound Ablation System**: Developed by Shenzhen Maiwei Medical Technology Co., Ltd., this device targets resistant hypertension through ultrasound energy to ablate renal nerves [41]. - **Bipolar High-Frequency Ultrasound Dual-Output Surgical Device**: Created by Shanghai Yichao Medical Device Co., Ltd., this device innovatively adjusts energy output based on tissue characteristics [42]. - **Kidney Puncture Surgical Navigation System**: Offered by Shenzhen Weide Precision Medical Technology Co., Ltd., this system utilizes AI for 3D reconstruction to assist in surgical navigation [45]. - **Transcatheter Aortic Valve Replacement Surgical Assistance System**: Developed by Zhicheng Medical Technology (Jiaxing) Co., Ltd., this system features modular design and tactile feedback for improved navigation in complex vascular conditions [45]. - **Disposable Hematoma Aspiration Device**: Produced by Shanghai Micron Medical Technology Co., Ltd., this device addresses the high mortality and disability rates associated with brain hemorrhages [46]. - **Proton Therapy System**: Launched by Meisheng Medical Equipment Co., Ltd., this system is recognized for its precision in targeting tumors while protecting surrounding tissues [47]. - **Continuous Glucose and Ketone Monitoring System**: Developed by Shenzhen Silicon-based Sensor Technology Co., Ltd., this system enhances diabetes management through continuous monitoring [48]. - **Biodegradable Zinc Alloy Internal Fixation System**: Created by Hunan Huaxiang Medical Technology Co., Ltd., this innovative product is aimed at addressing the need for biodegradable materials in medical applications [50]. - **Biological Artificial Blood Vessel**: Offered by Haima Medical Technology (Suzhou) Co., Ltd., this product is notable for its ability to produce small-diameter engineered blood vessels [51]. - **Disposable Fistula Closure Device**: Developed by Nanwei Medical Technology Co., Ltd., this device fills a gap in the market for post-operative fistula management [51]. - **Soft Tissue Release System**: Created by Ruilan Medical Technology (Shanghai) Co., Ltd., this product is designed for soft tissue expansion and cutting [52]. Group 3: Emerging Technologies - **Ultrasound Endoscopic Image Processing Device**: Developed by Hunan Kaimai Medical Technology Co., Ltd., this device enhances visualization during endoscopic procedures [57]. - **Self-Testing Mobile ECG Device**: Offered by Shenzhen Rui'Aixin Mobile ECG Information Service Co., Ltd., this portable device allows users to conduct ECG tests anywhere [58]. - **Non-Invasive Intracranial Pressure Monitoring Device**: Developed by Dongnao Medical Technology (Tianjin) Co., Ltd., this device utilizes infrared light density analysis for pressure detection [59]. - **Transcranial Electrical Stimulation Treatment System**: Created by Shanghai Quellan Technology Co., Ltd., this system is aimed at assisting in the treatment of brain injury-related disorders [59]. - **Cryogenic Wart Removal Spray**: Launched by Xiamen Zhongke Medical Device Co., Ltd., this product employs gas expansion for rapid freezing of warts [60]. - **Nasal Hemostasis Kit**: Developed by Hangzhou Yuan'ao Biotechnology Co., Ltd., this kit is designed for use in surgical and emergency settings [60]. - **Optical Coherence Tomography Scanner for Ophthalmology**: Offered by Gao Shi Innovation Technology Co., Ltd., this device is used for diagnosing retinal diseases [61]. - **Oral Suction Holder**: Created by Sichuan Lanqi Medical Device Co., Ltd., this product is designed for dental applications [62]. - **Ultrasound Imaging Processing Software**: Developed by Feiyinuo Technology (Changsha) Co., Ltd., this software aids in the analysis and storage of ultrasound images [64].

Group 1 - The core viewpoint of the article is that multiple shareholders of Jiukang Bio plan to transfer a total of 5% of their shares to China National Pharmaceutical Group [1] Group 2 - The article mentions that the controlling shareholder of Zai Sheng Technology intends to transfer 6.04% of the company's shares to Zhongrong Huaxin [5] - It also notes that Jiamei Packaging is planning a change of control, leading to a suspension of its stock [5] - Additionally, Shanshi Network Technology's shareholders plan to reduce their holdings by no more than 1% of the company's shares [5]